Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M77.7Revenue $M0Net Margin (%)0Z-Score-0.8
Enterprise Value $M49.1EPS $-0.8Operating Margin %0F-Score3
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %-8.8Quick Ratio17.4Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %1.1Current Ratio17.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-55.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-79.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M23.6ROI % (ttm)-7,524.8Gross Margin Increase y-yN

Gurus Latest Trades with GALT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GALTGeorge Soros 2014-06-30 Sold Out -0.01%$10.23 - $14.81
($12.43)
$ 3.29-278%Sold Out0
GALTGeorge Soros 2014-03-31 Buy 0.01%$8.025 - $18.3
($14.02)
$ 3.29-326%New holding48,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GALT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


GALT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
AMELIO GILBERT FDirector 2014-12-15Sell110$3.69-10.84 view
Greenberg ArthurDirector 2014-08-19Buy1,000$4.56-27.85 view
FREEMAN KEVIN DDirector 2014-08-15Buy1,000$4.7-30 view
TRABER PETER GPresident and CEO 2014-08-14Buy4,000$4.46-26.23 view
CALLICUTT JACK WCFO 2014-08-14Buy1,000$4.55-27.69 view
TRABER PETER GPresident and CEO 2014-08-13Buy1,000$4.42-25.57 view
Prelack StevenDirector 2014-04-11Sell6,000$11.84-72.21 view
Martin Rod DDirector 2014-01-13Sell100,000$14.84-77.83 view
CZIRR JAMES CExecutive Chairman 2014-01-13Sell100,000$14.84-77.83 view
10X Fund, L.P.10% Owner 2014-01-13Sell100,000$14.84-77.83 view

Press Releases about GALT :

    Quarterly/Annual Reports about GALT:

    News about GALT:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    RedChip Announces Presentation Schedule for Its April 22-23 Online Investor Conference Apr 15 2015
    GALECTIN THERAPEUTICS INC Financials Mar 25 2015
    Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of... Mar 24 2015
    Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of... Mar 24 2015
    Galectin Therapeutics reports 4Q loss Mar 18 2015
    Galectin Therapeutics reports 4Q loss Mar 18 2015
    Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update Mar 18 2015
    Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update Mar 18 2015
    GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 18 2015
    The Shuman Law Firm Investigates Galectin Therapeutics, Inc. Mar 17 2015
    Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special... Mar 12 2015
    Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special... Mar 12 2015
    GALECTIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Mar 12 2015
    Galectin Therapeutics to Present at the 27th Annual ROTH Conference Mar 02 2015
    Galectin Therapeutics to Present at the 27th Annual ROTH Conference Mar 02 2015
    Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02 Feb 24 2015
    GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 24 2015
    Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02 Feb 24 2015
    Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for... Jan 07 2015
    GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 07 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK